Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deals
Biotech
Tempus AI in line for $200M from AstraZeneca cancer model deal
Tempus has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based model that could be used to develop new cancer drugs.
James Waldron
Apr 23, 2025 9:01am
Boehringer slots synthetic lethal program into oncology pipeline
Apr 23, 2025 7:45am
Genentech builds autoimmune Repertoire with $765M deal
Apr 23, 2025 7:00am
Sanofi hands cancer drug to Innate as it pivots R&D pact focus
Apr 23, 2025 6:35am
German cancer antibody biotech eyes SPAC as route to Nasdaq
Apr 23, 2025 6:09am
Expect further market correction in tariff-driven era: PitchBook
Apr 18, 2025 7:51am
